Show simple item record

dc.contributor.authorLu, Christine
dc.contributor.authorZhang, Fang
dc.contributor.authorGolonski, Nicole
dc.contributor.authorLupton, Caitlin
dc.contributor.authorJeffrey, Paul L.
dc.contributor.authorWagner, Anita
dc.date2022-08-11T08:08:06.000
dc.date.accessioned2022-08-23T15:42:39Z
dc.date.available2022-08-23T15:42:39Z
dc.date.issued2017-11-07
dc.date.submitted2017-12-12
dc.identifier.citationChristine Y. Lu, Fang Zhang, Nicole Golonski, Caitlin Lupton, Paul Jeffrey, Anita K. Wagner. State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015. Value in Health, 2017, https://doi.org/10.1016/j.jval.2017.09.011.
dc.identifier.doi10.1016/j.jval.2017.09.011
dc.identifier.urihttp://hdl.handle.net/20.500.14038/26902
dc.description.abstractNew direct-acting antivirals have the ability to cure chronic hepatitis C virus infection, but the costs of these treatments and the number of patients that need them could bring about financial struggles for health systems. This journal article examines Medicaid reimbursement for HCV medications in the periods before and after the aforementioned direct-acting antivirals were made available. The report also analyzes the the effect of Medicaid expansion on reimbursement for direct-acting antivirals.
dc.language.isoen_US
dc.relation.urlhttps://doi.org/10.1016/j.jval.2017.09.011
dc.subjectDAAs
dc.subjectdirect-acting antivirals
dc.subjecthepatitis C
dc.subjectMedicaid
dc.subjectsofosbuvir
dc.subjectspecialty drugs
dc.subjectHealth Economics
dc.subjectHealth Law and Policy
dc.subjectHealth Policy
dc.subjectHealth Services Administration
dc.subjectHealth Services Research
dc.subjectPharmacoeconomics and Pharmaceutical Economics
dc.subjectVirus Diseases
dc.titleState Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015
dc.typeJournal Article
dc.source.journaltitleValue in Health
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/commed_pubs/137
dc.identifier.contextkey11237518
html.description.abstract<p>New direct-acting antivirals have the ability to cure chronic hepatitis C virus infection, but the costs of these treatments and the number of patients that need them could bring about financial struggles for health systems.</p> <p>This journal article examines Medicaid reimbursement for HCV medications in the periods before and after the aforementioned direct-acting antivirals were made available. The report also analyzes the the effect of Medicaid expansion on reimbursement for direct-acting antivirals.</p>
dc.identifier.submissionpathcommed_pubs/137
dc.contributor.departmentCommonwealth Medicine, Center for Health Policy and Research


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record